<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379247</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719XUS06T</org_study_id>
    <nct_id>NCT02379247</nct_id>
  </id_info>
  <brief_title>BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer</brief_title>
  <official_title>Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Priyanka Sharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in&#xD;
      locally recurrent or metastatic HER-2 negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most common cancer and the second leading cause of cancer related death&#xD;
      in American women. Despite recent improvement in the treatment of breast cancer, 40,000 women&#xD;
      still die each year in the US as a result of breast cancer. Chemotherapy (usually consisting&#xD;
      of sequential single agent) remains the backbone of treatment for patients with HER-2&#xD;
      negative metastatic breast cancer. A majority of patients show an initial response to&#xD;
      treatment, but all eventually show disease progression.&#xD;
&#xD;
      The purpose of this study is to determine the highest dose of BYL719 (alpelisib) combined&#xD;
      with Nab-Paclitaxel that results in no serious side effects. The safety and effectiveness of&#xD;
      BYL719 combined with Nab-Paclitaxel to treat patients with HER-2 negative metastatic breast&#xD;
      cancer will be assessed, along with the determination of how long this drug combination will&#xD;
      keep the disease from getting worse.&#xD;
&#xD;
      The study will be done in two parts:&#xD;
&#xD;
      Part 1 will determine the highest dose of BYL719 that is safe and tolerable to take in&#xD;
      combination with Nab-Paclitaxel. Part 1 will be completed before Part 2 begins.&#xD;
&#xD;
      Part 2 will investigate whether taking BYL719 (at the dose determined in Part 1) +&#xD;
      Nab-Paclitaxel is safe and effective for patients with HER-2 negative metastatic breast&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Phase I was a 3+3 dose escalation design (three dose levels of alpelisib: 250mg, 300mg, and 350mg orally once daily, continuous dosing) with dose-limiting toxicities (DLT) assessed during the first treatment cycle. If two or more of the six patients experienced a dose-limiting toxicity, dosing escalation would cease and maximum tolerated dose (MTD) would be reached. RP2D was the next lower dose at which &lt;1/6 subjects experienced a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall Response Rate (ORR) of Subjects Treated at the Recommended Phase II Dose (RP2D)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR includes complete response (CR) plus partial response (PR). As evaluated per RECIST version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) at 16 Weeks of Study Treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>CBR includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks. As evaluated per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BYL-719 (Alpelisib) When Administered With Nab-paclitaxel</measure>
    <time_frame>In cycle 1 day 1, from prior to alpelisib dosing through 8 hours after alpelisib dosing</time_frame>
    <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-alpelisib dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of (Total) Nab-paclitaxel When Administered With BYL-719 (Alpelisib)</measure>
    <time_frame>In cycle 1 day 1, from prior to alpelisib dosing through 8 hours after alpelisib dosing</time_frame>
    <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, and 6 hours post-alpelisib dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) and Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>PFS was defined as the time in months from the date of enrollment to the date of progression or death, whichever was earlier. OS was defined as the time in months from the date of enrollment to death as a result of any cause. Survival curves were assessed by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of PIK3CA Mutation With Clinical Benefit Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of clinical benefit rate between participants with and without PIK3CA mutation in tumor tissue and/or circulating tumor DNA. Clinical benefit rate includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks, as evaluated per RECIST version 1.1. Tumor DNA was isolated from archived formalin-fixed, paraffin-embedded tumor tissue (primary or metastatic site) and subjected to next-generation sequencing for assessment of PIK3CA mutation using ONCOReveal Multi-Cancer Panel (Pillar Biosciences). Circulating tumor DNA was isolated from pre-treatment plasma samples and subjected to next-generation sequencing for assessment of PIK3CA mutation using FoundationOne CDx testing or ONCOReveal Multi-Cancer Panel.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL-719 (alpelisib): 250mg daily on day 1-28&#xD;
Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYL-719 (alpelisib) Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL-719 (alpelisib)</intervention_name>
    <description>Oral PI3K inhibitor</description>
    <arm_group_label>BYL-719 (alpelisib) Dose Expansion</arm_group_label>
    <arm_group_label>Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_label>Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_label>Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel</arm_group_label>
    <other_name>Piqray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>IV taxane</description>
    <arm_group_label>BYL-719 (alpelisib) Dose Expansion</arm_group_label>
    <arm_group_label>Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_label>Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel</arm_group_label>
    <arm_group_label>Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written Informed Consent Form.&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically proven HER-2 negative breast cancer (HER-2 negative defined as HER IHC&#xD;
             0 or 1+ and/or HER-2 FISH negative); HER-2 negative breast cancer includes hormone&#xD;
             positive (ER and/or PR positive) breast cancer and TNBC&#xD;
&#xD;
          4. HER-2 negative breast cancer that at the time of study entry is either stage III&#xD;
             (locally advanced) disease not amenable to curative therapy or stage IV disease.&#xD;
             Histological confirmation of recurrent/metastatic disease is encouraged but not&#xD;
             required if clinical evidence of stage IV disease is available&#xD;
&#xD;
          5. Have measurable (defined as at least one lesion that can be accurately measured in at&#xD;
             least one dimension [longest diameter to be recorded] with minimum lesion size of ≥ 2&#xD;
             cm on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT)&#xD;
             scan&#xD;
&#xD;
          6. No limitations to number of prior chemotherapies for metastatic disease. Treatment&#xD;
             with prior taxanes (except Nab-Paclitaxel) is allowed as long as it has been 6 months&#xD;
             or more since exposure to prior taxane.&#xD;
&#xD;
             NOTE: For subjects who are, or who have previously received endocrine therapy for&#xD;
             breast cancer, the treating investigator will decide how many days should pass between&#xD;
             the last dose of endocrine therapy and the first dose of study treatment.&#xD;
&#xD;
          7. All patients should have received at least one line of chemotherapy in either the&#xD;
             advanced or adjuvant setting and hormonal therapy (where appropriate)&#xD;
&#xD;
          8. Performance status of 2 or better as per ECOG criteria (See Appendix A for details)&#xD;
&#xD;
          9. Subject is able to swallow and retain oral medicines&#xD;
&#xD;
         10. Adequate marrow and organ function as defined below (labs must be performed within 14&#xD;
             days of subject registration)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1500/uL&#xD;
&#xD;
               -  Platelets 100,000/uL (no transfusion allowed within 2 weeks)&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL (which may be reached by transfusion)&#xD;
&#xD;
               -  Total bilirubin within normal range or ≤ 1.5X IULN if liver metastases are&#xD;
                  present or total bilirubin ≤ 3.0X IULN with direct bilirubin within normal range&#xD;
                  in subjects with well-documented Gilbert's Syndrome, which is defined as presence&#xD;
                  of unconjugated hyperbilirubinemia with normal results from CBC (including normal&#xD;
                  reticulocyte count and blood smear), normal liver function test results and&#xD;
                  absence of other contributing disease processes at the time of diagnosis&#xD;
&#xD;
               -  AST(SGOT)/ALT(SPGT) ≤ 2.5X IULN or ≤ 5X IULN if liver metastases are present&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5X IULN&#xD;
&#xD;
               -  INR ≤ 1.5&#xD;
&#xD;
               -  Fasting plasma glucose ≤ 140 mg/dL or 7.8 mmol/L (NOTE: Fasting whole blood&#xD;
                  glucose testing is acceptable if fasting plasma glucose is not feasible.)&#xD;
&#xD;
               -  HBA1c ≤ 8%&#xD;
&#xD;
               -  Potassium, calcium (corrected for serum albumin) and magnesium within IULN&#xD;
&#xD;
               -  Serum Amylase &lt; 2 x ULN and serum lipase within normal limits&#xD;
&#xD;
         11. IV bisphosphate and denosumab for bony metastatic disease will be allowed&#xD;
&#xD;
         12. Prior palliative radiation therapy to bony metastases is allowed. There should be a&#xD;
             minimum of 14 days between the end of radiation treatment and start of study treatment&#xD;
&#xD;
         13. Subjects with previously treated brain metastases who are free of CNS symptoms and are&#xD;
             &gt; 3 months from treatment of brain metastases are eligible Subjects should be &gt; 2&#xD;
             weeks from prior systemic chemotherapy for breast cancer AND should have recovered to&#xD;
             Grade 1 or better (except alopecia) from related side effects of any prior&#xD;
             antineoplastic therapy prior to study entry NOTE: For subjects who are, or who have&#xD;
             previously received endocrine therapy for breast cancer, the treating investigator&#xD;
             will decide how many days should pass between the last dose of endocrine therapy and&#xD;
             the first dose of study treatment.&#xD;
&#xD;
         14. Women of child bearing potential (WOCBP) and their partners must agree to use adequate&#xD;
             contraception (barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 90 days following completion of therapy.&#xD;
             After confirmation of negative pregnancy test at screening, should a WOCBP become&#xD;
             pregnant or suspect that she is pregnant while participating in this study, she should&#xD;
             inform her treating physician and the investigator immediately.&#xD;
&#xD;
               -  WOCBP are defined as any females (regardless of sexual orientation, having&#xD;
                  undergone tubal ligation, or remaining celibate by choice) who meet the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Have not undergone a hysterectomy or bilateral oophorectomy OR&#xD;
&#xD;
                    -  Have not been naturally postmenopausal for at least 12 consecutive months&#xD;
                       (i.e. has had menses at any time in the preceding 12 consecutive months)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject has any other medical or psychiatric disorder that, in the opinion of the&#xD;
             treating physician, would contraindicate the use of drugs in this protocol or place&#xD;
             the subject at undue risk for treatment complications&#xD;
&#xD;
          2. Subject is pregnant or lactating&#xD;
&#xD;
          3. Subject has previously been treated with Nab-Paclitaxel NOTE: Subjects who have had&#xD;
             previous treatment with Nab-Paclitaxel will NOT be excluded if given in the adjuvant&#xD;
             or neoadjuvant setting Only in the metastatic setting, will subjects previously&#xD;
             treated with Nab-Paclitaxel be excluded from this trial. Exceptions may be made for&#xD;
             subjects who discontinued treatment with a previous Nab-Paclitaxel inhibitor for&#xD;
             reasons other than progression and as long as it has been &gt; 12 months since&#xD;
             discontinuation of the previous Nab-Paclitaxel. This exception will require prior&#xD;
             approval from the study PI at KUMC.&#xD;
&#xD;
          4. Subject has inflammatory breast cancer&#xD;
&#xD;
          5. Subject has a known hypersensitivity to any of the excipients of Nab-Paclitaxel or&#xD;
             BYL719/alpelisib&#xD;
&#xD;
          6. Subject has a concurrent malignancy or malignancy within 3 years of study enrollment&#xD;
             (with the exception of adequately treated, basal or squamous cell carcinoma,&#xD;
             non-melanomatous skin cancer or curatively resected cervical cancer)&#xD;
&#xD;
          7. Subject has clinically manifest diabetes mellitus or documented steroid-induced&#xD;
             diabetes mellitus&#xD;
&#xD;
          8. Subject has impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of the study drugs (e.g. ulcerative diseases,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel&#xD;
             resection)&#xD;
&#xD;
          9. Subject is classified into Child-Pugh class C&#xD;
&#xD;
         10. Subject has a known history of HIV infection (testing not mandatory)&#xD;
&#xD;
         11. Subject has active, uncontrolled infection&#xD;
&#xD;
         12. Subject has symptomatic/untreated CNS disease&#xD;
&#xD;
         13. Subject has ≥ Grade 2 peripheral neuropathy&#xD;
&#xD;
         14. Subject has active cardiac disease or a history of cardiac dysfunction including any&#xD;
             of the following:&#xD;
&#xD;
               -  Unstable angina pectoris within 6 months prior to study entry&#xD;
&#xD;
               -  Symptomatic peritonitis&#xD;
&#xD;
               -  Documented myocardial infarction within 6 months prior to study entry&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
               -  Subject has a Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by&#xD;
                  Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO)&#xD;
&#xD;
               -  Subject has any of the following cardiac conduction abnormalities&#xD;
&#xD;
               -  Ventricular arrhythmias except for benign premature ventricular contractions&#xD;
&#xD;
               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled&#xD;
                  with medicine&#xD;
&#xD;
               -  Conduction abnormality requiring a pacemaker&#xD;
&#xD;
               -  Other cardiac arrhythmia not controlled with medication&#xD;
&#xD;
         15. Subject has a QTcF &gt; 480 msec on the screening ECG (using the QTcF formula)&#xD;
&#xD;
         16. Subject is currently receiving treatment with a medication that has a known risk to&#xD;
             prolong the QT interval or induce Torsades de Pointes and the treatment cannot be&#xD;
             discontinued or switched to a different medication prior to randomization&#xD;
&#xD;
         17. Subject has had major surgery within 14 days prior to starting study drug or has not&#xD;
             recovered from major side effects&#xD;
&#xD;
         18. Subject is currently receiving or has received systemic corticosteroids ≤ 2 weeks&#xD;
             prior to starting study drug or who have not fully recovered from side effects of such&#xD;
             treatment&#xD;
&#xD;
         19. Subject is currently receiving treatment with drugs known to be moderate or strong&#xD;
             inhibitors or inducers of isoenzyme CYP3A. The subject must have discontinued strong&#xD;
             inducers for at least one week and must have discontinued strong inhibitors before the&#xD;
             start of treatment&#xD;
&#xD;
         20. Subject is currently receiving warfarin or other coumarin-derived anti-coagulant for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH), or fondaparinux is allowed&#xD;
&#xD;
         21. Subject has received previous treatment with a PI3K inhibitor. Exceptions may be made&#xD;
             for subjects who discontinued treatment with a previous PI3K inhibitor for reasons&#xD;
             other than toxicity or progression and as long as it has been &gt; 12 months since&#xD;
             discontinuation of the previous PI3K inhibitor. This exception will require prior&#xD;
             approval from the study PI at KUMC.&#xD;
&#xD;
         22. Subjects who have received an investigational agent within 30 days OR within 5&#xD;
             half-lives of the investigational agent (whichever is shorter) prior to the possible&#xD;
             enrollment date on this study.&#xD;
&#xD;
         23. Subject with history of acute within one year of study entry or past medical history&#xD;
             of chronic pancreatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priyanka Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sharma P, Abramson VG, O'Dea A, Nye L, Mayer I, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson SK, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. doi: 10.1158/1078-0432.CCR-20-4879. Epub 2021 Feb 18.</citation>
    <PMID>33602685</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>May 7, 2021</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Priyanka Sharma</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>HER-2 Negative</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02379247/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1 BYL-719/Alpelisib (250mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 250mg daily on day 1-28&#xD;
Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)&#xD;
BYL-719 (alpelisib): Oral PI3K inhibitor&#xD;
Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2 BYL-719 (Alpelisib) (300mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)&#xD;
BYL-719 (alpelisib): Oral PI3K inhibitor&#xD;
Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3 BYL-719 (Alpelisib) (350mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)&#xD;
BYL-719 (alpelisib): Oral PI3K inhibitor&#xD;
Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="P4">
          <title>BYL-719 (Alpelisib) Dose Expansion</title>
          <description>BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle&#xD;
Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)&#xD;
BYL-719 (alpelisib): Oral PI3K inhibitor&#xD;
Nab-paclitaxel: IV taxane</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1 BYL-719/Alpelisib (250mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 250mg daily on day 1-28 Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2 BYL-719/Alpelisib (300mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 300mg daily on day 1-28 Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="B3">
          <title>Dose Level 3 BYL-719/Alpelisib (350mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 350mg daily on day 1-28 Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="B4">
          <title>BYL-719/Alpelisib Dose Expansion</title>
          <description>BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="41" upper_limit="65"/>
                    <measurement group_id="B2" value="61" lower_limit="51" upper_limit="62"/>
                    <measurement group_id="B3" value="59" lower_limit="52" upper_limit="68"/>
                    <measurement group_id="B4" value="54" lower_limit="34" upper_limit="72"/>
                    <measurement group_id="B5" value="55" lower_limit="34" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastatic disease subtype</title>
          <description>Estrogen receptor and progesterone receptor positivity was defined as ≥10% by immunohistochemistry. HER2 positivity was defined per 2013 ASCO/CAP guidelines (Wolff et al, J Clin Oncol 2013;31(31):3997-4013. Triple negativity was defined as estrogen receptor negative, progesterone receptor negative, and HER2 negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Estrogen receptor and/or progesterone receptor positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triple-negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Measurable disease</title>
          <description>Presence of measurable disease according to RECIST version 1.1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral disease</title>
          <description>Presence of at least one visceral metastatic site</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Present</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior lines of chemotherapy for metastatic disease</title>
          <description>Number of prior lines of chemotherapy for metastatic disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior taxane</title>
          <description>Prior receipt of a taxane, and in what treatment setting(s) a taxane was received.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Neoadjuvant or adjuvant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic only</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoadjuvant or adjuvant AND metastatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior CDK4/6 inhibitor</title>
          <description>Prior receipt of any CDK4/6 inhibitor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="30"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer</title>
        <description>Phase I was a 3+3 dose escalation design (three dose levels of alpelisib: 250mg, 300mg, and 350mg orally once daily, continuous dosing) with dose-limiting toxicities (DLT) assessed during the first treatment cycle. If two or more of the six patients experienced a dose-limiting toxicity, dosing escalation would cease and maximum tolerated dose (MTD) would be reached. RP2D was the next lower dose at which &lt;1/6 subjects experienced a DLT.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>All patients in phase I, across all three dose levels of BYL-719 (alpelisib) + nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer</title>
          <description>Phase I was a 3+3 dose escalation design (three dose levels of alpelisib: 250mg, 300mg, and 350mg orally once daily, continuous dosing) with dose-limiting toxicities (DLT) assessed during the first treatment cycle. If two or more of the six patients experienced a dose-limiting toxicity, dosing escalation would cease and maximum tolerated dose (MTD) would be reached. RP2D was the next lower dose at which &lt;1/6 subjects experienced a DLT.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II: Overall Response Rate (ORR) of Subjects Treated at the Recommended Phase II Dose (RP2D)</title>
        <description>ORR includes complete response (CR) plus partial response (PR). As evaluated per RECIST version 1.1.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Treated at the RP2D</title>
            <description>Participants who were treated at the RP2D (350 mg BYL-719/alpelisib + 100 mg/m2 nab-paclitaxel) in either phase I or phase II.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Overall Response Rate (ORR) of Subjects Treated at the Recommended Phase II Dose (RP2D)</title>
          <description>ORR includes complete response (CR) plus partial response (PR). As evaluated per RECIST version 1.1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR) at 16 Weeks of Study Treatment</title>
        <description>CBR includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks. As evaluated per RECIST version 1.1.</description>
        <time_frame>16 weeks</time_frame>
        <population>Per protocol the endpoint of CBR at 16 weeks is to be reported for all participants in phase I and phase II who were evaluable for response, thus participants from all assigned dose levels are combined for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Evaluable Participants</title>
            <description>All participants in phase I and phase II who were evaluable for response (i.e. received at least one cycle of study treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR) at 16 Weeks of Study Treatment</title>
          <description>CBR includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks. As evaluated per RECIST version 1.1.</description>
          <population>Per protocol the endpoint of CBR at 16 weeks is to be reported for all participants in phase I and phase II who were evaluable for response, thus participants from all assigned dose levels are combined for this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of BYL-719 (Alpelisib) When Administered With Nab-paclitaxel</title>
        <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-alpelisib dose</description>
        <time_frame>In cycle 1 day 1, from prior to alpelisib dosing through 8 hours after alpelisib dosing</time_frame>
        <population>Pharmacokinetic measures were assessed only among participants in phase I.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Participants assigned to dose level 1 BYL-719/Alpelisib (250mg)+Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Participants assigned to Dose Level 2 BYL-719/Alpelisib (300mg)+Nab-paclitaxel</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>Participants in phase I assigned to dose level 3 BYL-719/Alpelisib (350mg)+Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of BYL-719 (Alpelisib) When Administered With Nab-paclitaxel</title>
          <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-alpelisib dose</description>
          <population>Pharmacokinetic measures were assessed only among participants in phase I.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6846" spread="3410"/>
                    <measurement group_id="O2" value="12436" spread="6174"/>
                    <measurement group_id="O3" value="13359" spread="5798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of (Total) Nab-paclitaxel When Administered With BYL-719 (Alpelisib)</title>
        <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, and 6 hours post-alpelisib dose</description>
        <time_frame>In cycle 1 day 1, from prior to alpelisib dosing through 8 hours after alpelisib dosing</time_frame>
        <population>Pharmacokinetic measures were assessed only among participants in phase I. One phase I participant assigned to the 350 mg BYL-719 (alpelisib) dose level did not have an end-of-infusion sample for paclitaxel measurement. Data are based on 12 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Participants assigned to dose level 1 BYL-719/Alpelisib (250mg)+Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Participants assigned to dose level 2 BYL-719/Alpelisib (300mg)+Nab-paclitaxel</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>Participants in phase I assigned to dose level 3 BYL-719/Alpelisib (350mg)+Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of (Total) Nab-paclitaxel When Administered With BYL-719 (Alpelisib)</title>
          <description>Area under the curve (AUC): sampling pre-dose and 1.5, 2, 2.5, 3, 3.5, 4, and 6 hours post-alpelisib dose</description>
          <population>Pharmacokinetic measures were assessed only among participants in phase I. One phase I participant assigned to the 350 mg BYL-719 (alpelisib) dose level did not have an end-of-infusion sample for paclitaxel measurement. Data are based on 12 participants.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8488" spread="1537"/>
                    <measurement group_id="O2" value="9938" spread="1735"/>
                    <measurement group_id="O3" value="6979" spread="2492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) and Overall Survival (OS)</title>
        <description>PFS was defined as the time in months from the date of enrollment to the date of progression or death, whichever was earlier. OS was defined as the time in months from the date of enrollment to death as a result of any cause. Survival curves were assessed by the Kaplan-Meier method.</description>
        <time_frame>36 months</time_frame>
        <population>Per protocol the endpoints of PFS and OS are to be reported for all participants in phase I and phase II who were evaluable for response, thus participants from all assigned dose levels are combined for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Evaluable Participants</title>
            <description>All participants in phase I and phase II who were evaluable for response (i.e. received at least one cycle of study treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) and Overall Survival (OS)</title>
          <description>PFS was defined as the time in months from the date of enrollment to the date of progression or death, whichever was earlier. OS was defined as the time in months from the date of enrollment to death as a result of any cause. Survival curves were assessed by the Kaplan-Meier method.</description>
          <population>Per protocol the endpoints of PFS and OS are to be reported for all participants in phase I and phase II who were evaluable for response, thus participants from all assigned dose levels are combined for this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression-free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="5.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="9.6" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of PIK3CA Mutation With Clinical Benefit Rate</title>
        <description>Comparison of clinical benefit rate between participants with and without PIK3CA mutation in tumor tissue and/or circulating tumor DNA. Clinical benefit rate includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks, as evaluated per RECIST version 1.1. Tumor DNA was isolated from archived formalin-fixed, paraffin-embedded tumor tissue (primary or metastatic site) and subjected to next-generation sequencing for assessment of PIK3CA mutation using ONCOReveal Multi-Cancer Panel (Pillar Biosciences). Circulating tumor DNA was isolated from pre-treatment plasma samples and subjected to next-generation sequencing for assessment of PIK3CA mutation using FoundationOne CDx testing or ONCOReveal Multi-Cancer Panel.</description>
        <time_frame>24 months</time_frame>
        <population>Among 42 participants evaluable for response, 17 had PIK3CA mutation in tumor tissue and/or circulating tumor DNA, while 25 did not. Clinical benefit rate was assessed among participants with PIK3CA mutation separately from participants without PIK3CA mutation for the purpose of correlating clinical benefit rate with PIK3CA mutation status. Per protocol the analysis is reported for all participants evaluable for response, thus participants from all dose levels are combined for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Evaluable Participants</title>
            <description>All participants in phase I and phase II who were evaluable for response (i.e. received at least one cycle of study treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of PIK3CA Mutation With Clinical Benefit Rate</title>
          <description>Comparison of clinical benefit rate between participants with and without PIK3CA mutation in tumor tissue and/or circulating tumor DNA. Clinical benefit rate includes complete response (CR), partial response (PR), plus stable disease (SD) ≥16 weeks, as evaluated per RECIST version 1.1. Tumor DNA was isolated from archived formalin-fixed, paraffin-embedded tumor tissue (primary or metastatic site) and subjected to next-generation sequencing for assessment of PIK3CA mutation using ONCOReveal Multi-Cancer Panel (Pillar Biosciences). Circulating tumor DNA was isolated from pre-treatment plasma samples and subjected to next-generation sequencing for assessment of PIK3CA mutation using FoundationOne CDx testing or ONCOReveal Multi-Cancer Panel.</description>
          <population>Among 42 participants evaluable for response, 17 had PIK3CA mutation in tumor tissue and/or circulating tumor DNA, while 25 did not. Clinical benefit rate was assessed among participants with PIK3CA mutation separately from participants without PIK3CA mutation for the purpose of correlating clinical benefit rate with PIK3CA mutation status. Per protocol the analysis is reported for all participants evaluable for response, thus participants from all dose levels are combined for this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PIK3CA mutation present</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA mutation absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each participant, treatment-related adverse events were collected from start of study treatment until 30 days after the participant's last dose of study treatment, assessed up to 174 weeks, whichever came first. All-cause mortality was collected from start of study treatment through October 16, 2019 (data cutoff date).</time_frame>
      <desc>Adverse events (serious and non-serious) of all grades, definitely related/probably related/possibly related to study treatment, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Patients were systematically evaluated for toxicity at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1 BYL-719/Alpelisib (250mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 250mg daily on day 1-28 of each 28 day cycle Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 2 BYL-719/Alpelisib (300mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 300mg daily on day 1-28 of each 28 day cycle Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="E3">
          <title>Dose Level 3 BYL-719/Alpelisib (350mg)+Nab-paclitaxel</title>
          <description>BYL-719 (alpelisib): 350mg daily on day 1-28 of each 28 day cycle Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
        <group group_id="E4">
          <title>BYL-719 (Alpelisib) Dose Expansion</title>
          <description>BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day) BYL-719 (alpelisib): Oral PI3K inhibitor Nab-paclitaxel: IV taxane</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Decreased lymphocyte count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - other</sub_title>
                <description>Grade 2 colitis (n=1); grade 1 stomach tightness (n=1); and grade 1 unspecified gastrointestinal disorder (n=1).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver enzyme increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <description>Grade 3 generalized muscle weakness (n=1); grade 2 muscle weakness lower limb (n=2); grade 1 events (n=1 each): muscle weakness lower limb, left arm pain, generalized muscle weakness, and toe pain.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry skin/mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Priyanka Sharma</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>9135886079</phone>
      <email>psharma2@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

